Discover how Evelo’s EDP1815 may prevent the progression of COVID-19. Learn More

skip to content

News

EVELO BIOSCIENCES REPORTS FIRST QUARTER FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS
Cambridge, MA - May 11, 2020

EVELO BIOSCIENCES, RUTGERS UNIVERSITY, AND ROBERT WOOD JOHNSON UNIVERSITY HOSPITAL ANNOUNCE SUBMISSION OF IND FOR A PHASE 2 STUDY OF EDP1815 IN COVID-19 PATIENTS
Cambridge, MA - May 7, 2020

EVELO BIOSCIENCES TO REPORT FIRST QUARTER 2020 FINANCIAL RESULTS ON MONDAY, MAY 11, 2020
Cambridge, MA - May 4, 2020

EVELO BIOSCIENCES APPOINTS NEIL GRAHAM, M.D., M.B.B.S., M.P.H., AS CHIEF DEVELOPMENT OFFICER
Cambridge, MA - April 15, 2020

EVELO BIOSCIENCES ANNOUNCES BIOMARKER DATA SHOWING EDP1815 IS AN ORALLY DELIVERED DUAL CYTOKINE INHIBITOR FOR INFLAMMATORY DISEASES
Cambridge, MA - March 2, 2020

EVELO BIOSCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS
Cambridge, MA - February 13, 2020

EVELO BIOSCIENCES TO REPORT FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS ON THURSDAY, FEBRUARY 13, 2020
Cambridge, MA - February 6, 2020

EVELO PROVIDES UPDATE ON RECENT POSITIVE EDP1815 REGULATORY INTERACTIONS ON PHASE 2 TRIAL DESIGN RESULTING IN SHORTER DEVELOPMENT TIMELINE TO REGISTRATION
Cambridge, MA - January 10, 2020

EVELO BIOSCIENCES APPOINTS JUAN ANDRES TO BOARD OF DIRECTORS
Cambridge, MA - December 5, 2019

EVELO BIOSCIENCES TO PRESENT PRECLINICAL DATA FROM ITS EDP1503 ONCOLOGY PROGRAM AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER’S (SITC) ANNUAL MEETING
Cambridge, MA - November 8, 2019

EVELO BIOSCIENCES REPORTS FURTHER POSITIVE EDP1815 INTERIM CLINICAL DATA IN PATIENTS WITH PSORIASIS AT HIGH DOSE IN PHASE 1B TRIAL
Cambridge, MA - November 5, 2019

EVELO BIOSCIENCES ANNOUNCES FURTHER POSITIVE INTERIM PHASE 1B CLINICAL DATA IN PSORIASIS AND REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS
Cambridge, MA - November 5, 2019

EVELO BIOSCIENCES TO HOST QUARTERLY CORPORATE UPDATE CONFERENCE CALL ON TUESDAY, NOVEMBER 5TH
Cambridge, MA - October 29, 2019

EVELO BIOSCIENCES TO HOST KEY OPINION LEADER SYMPOSIUM ON UNMET NEED IN MILD TO MODERATE PSORIASIS AND POTENTIAL FOR EDP1815
Cambridge, MA - October 2, 2019

EVELO BIOSCIENCES TO PRESENT AT THE 2019 CANTOR GLOBAL HEALTHCARE CONFERENCE
Cambridge, MA - October 2, 2019

EVELO BIOSCIENCES ANNOUNCES THE APPOINTMENT OF DAVID EPSTEIN AS CHAIRMAN OF ITS BOARD OF DIRECTORS
Cambridge, MA - September 17, 2019

EVELO BIOSCIENCES TO PRESENT AT THE MORGAN STANLEY 17TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
Cambridge, MA - September 3, 2019

EVELO BIOSCIENCES REPORTS POSITIVE EDP1815 INTERIM CLINICAL DATA IN PSORIASIS PATIENTS AT LOW DOSE IN ONGOING PHASE 1B TRIAL
Cambridge, MA - August 6, 2019

EVELO BIOSCIENCES ANNOUNCES POSITIVE INTERIM PHASE 1B CLINICAL DATA AND PROVIDES SECOND QUARTER 2019 FINANCIAL RESULTS
Cambridge, MA - August 6, 2019

EVELO BIOSCIENCES TO HOST QUARTERLY CORPORATE UPDATE CONFERENCE CALL ON TUESDAY, AUGUST 6TH
Cambridge, MA - July 30, 2019

EVELO BIOSCIENCES SECURES $45 MILLION DEBT FINANCING FROM K2 HEALTHVENTURES
Cambridge, MA - July 25, 2019

EVELO BIOSCIENCES TO PRESENT AT UPCOMING INVESTOR CONFERENCES IN JUNE
Cambridge, MA - May 30, 2019

EVELO BIOSCIENCES TO PRESENT AT 2019 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE
Cambridge, MA - May 15, 2019

EVELO BIOSCIENCES REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS
Cambridge, Mass. - May 2, 2019

EVELO BIOSCIENCES TO HOST QUARTERLY CORPORATE UPDATE CONFERENCE CALL ON THURSDAY, MAY 2, 2019
Cambridge, Mass. - April 25, 2019

EVELO BIOSCIENCES TO PRESENT AT 18TH ANNUAL NEEDHAM HEALTHCARE CONFERENCE
Cambridge, Mass. - April 3, 2019

EVELO BIOSCIENCES TO PRESENT AT 39TH ANNUAL COWEN & CO. HEALTH CARE CONFERENCE
Cambridge, Mass. - March 4, 2019

EVELO BIOSCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS
Cambridge, Mass. - February 14, 2019

EVELO BIOSCIENCES TO REPORT FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS ON THURSDAY, FEBRUARY 14, 2019
Cambridge, Mass. - February 7, 2019

EVELO BIOSCIENCES ANNOUNCES DOSING OF FIRST PATIENT IN INVESTIGATOR-SPONSORED PHASE 2A CLINICAL TRIAL OF EDP1503 IN COMBINATION WITH KEYTRUDA® IN PATIENTS WITH METASTATIC MELANOMA
Cambridge, Mass. - January 28, 2019

EVELO BIOSCIENCES ANNOUNCES DOSING OF FIRST PATIENT IN PHASE 1/2 CLINICAL TRIAL OF EDP1503 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN MULTIPLE ONCOLOGY INDICATIONS
Cambridge, Mass. - January 4, 2019

EVELO ENTERS INTO CLINICAL TRIAL COLLABORATION AGREEMENT WITH MERCK
Cambridge, Mass. - November 27, 2018

EVELO BIOSCIENCES ANNOUNCES FIRST DOSING IN PHASE 1B CLINICAL TRIAL OF EDP1815 IN PSORIASIS AND ATOPIC DERMATITIS
Cambridge, Mass. - November 26, 2018

EVELO BIOSCIENCES REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS
Cambridge, Mass. - November 1, 2018

EVELO BIOSCIENCES REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS
Cambridge, Mass. - August 2, 2018

EVELO BIOSCIENCES ADDED TO RUSSELL 3000®, 2000® AND MICROCAP® INDEXES
Cambridge, Mass. - June 25, 2018

EVELO BIOSCIENCES TO PRESENT AT THE JMP SECURITIES 2018 LIFE SCIENCES CONFERENCE
Cambridge, Mass. - June 14, 2018

EVELO BIOSCIENCES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS
Cambridge, Mass. - May 31, 2018

EVELO BIOSCIENCES ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING
Cambridge, Mass. - May 8, 2018

EVELO BIOSCIENCES EXPANDS EXECUTIVE LEADERSHIP TEAM
Cambridge, Mass. - February 8, 2018

EVELO BIOSCIENCES ANNOUNCES ISSUANCE OF U.S. PATENT SUPPORTING MONOCLONAL MICROBIAL ONCOLOGY TRIALS
Cambridge, Mass. - January 9, 2018

EVELO BIOSCIENCES AND MAYO CLINIC COLLABORATE TO ADVANCE MONOCLONAL MICROBIALS FOR THE TREATMENT OF INFLAMMATORY AND NEUROINFLAMMATORY DISEASES
Cambridge, Mass. - November 16, 2017

EVELO BIOSCIENCES ANNOUNCES $50 MILLION SERIES B FINANCING AND EXPANSION OF BOARD AND LEADERSHIP TEAM
Cambridge, Mass. - July 11, 2017

EVELO BIOSCIENCES TO PRESENT AT BIOCENTURY NEWSMAKERS CONFERENCE
Cambridge, Mass. - September 6, 2016

EVELO BIOSCIENCES AND MAYO CLINIC ESTABLISH RESEARCH COLLABORATION FOR IMMUNO-MICROBIOME CANCER THERAPIES
Cambridge, Mass. - August 2, 2016

EVELO BIOSCIENCES AND EPIVA BIOSCIENCES MERGE TO CREATE THE LEADING IMMUNO-MICROBIOME COMPANY
Cambridge, Mass. - July 12, 2016

EVELO BIOSCIENCES PARTICIPATES IN WHITE HOUSE OFFICE OF SCIENCE AND TECHNOLOGY POLICY'S NATIONAL MICROBIOME INITIATIVE EVENT
Cambridge, Mass. - May 13, 2016

EVELO BIOSCIENCES ANNOUNCES PARTICIPATION AT GUGGENHEIM MICROBIOME DAY
Cambridge, Mass. - April 14, 2016

UCHICAGO AND EVELO BIOSCIENCES SIGN LICENSING DEAL FOR MICROBIOME-BASED CANCER IMMUNOTHERAPY
Cambridge, Mass. - April 7, 2016

EVELO BIOSCIENCES ESTABLISHES SCIENTIFIC ADVISORY BOARD
Cambridge, Mass. - March 29, 2016

EVELO THERAPEUTICS ESTABLISHES CORE EXECUTIVE TEAM
Cambridge, Mass. - January 11, 2016

EVELO THERAPEUTICS EXPANDS TO NEW HEADQUARTERS IN CAMBRIDGE
Cambridge, Mass. - December 18, 2015

UCHICAGO AND EVELO THERAPEUTICS PARTNER TO ADVANCE MICROBIOME-BASED CANCER IMMUNOTHERAPY
Cambridge, Mass. - November 9, 2015

FLAGSHIP VENTURES LAUNCHES EVELO THERAPEUTICS TO DEVELOP MICROBIOME THERAPIES FOR CANCER
Cambridge, Mass. - November 4, 2015